CervoMed says UK grants ILAP Innovation Passport for neflamapimod in Lewy body dementia
CRVO•UK pathway designation for neflamapimod
CervoMed says its neflamapimod received an Innovation Passport under the UK Innovative Licensing and Access Pathway for dementia with Lewy bodies.
The designation triggers coordinated regulatory and reimbursement engagement with MHRA, NHS, NICE, SMC, and AWTTC to support faster UK access.
CervoMed plans a Phase 3 trial for neflamapimod in dementia with Lewy bodies.
